---
canonical_name: Common Hawthorn
alternate_names: Crataegus monogyna, Crataegus laevigata, Crataegus oxyacantha, Hawthorn Berry, Hawthorn Leaf and Flower, Mayblossom, Whitethorn, English Hawthorn, One-Seed Hawthorn, Crataegi folium cum flore, Weissdorn, Aubepine, WS 1442
canonical_topic: Common Hawthorn for Health & Longevity
short_topic_lc: common_hawthorn
creation_date: 2026-0816-1311
creator_ai_fullname: Grok 4.5
---

# Common Hawthorn for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 08/16/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4.5

**Also known as:** Crataegus monogyna, Crataegus laevigata, Crataegus oxyacantha, Hawthorn Berry, Hawthorn Leaf and Flower, Mayblossom, Whitethorn, English Hawthorn, One-Seed Hawthorn, Crataegi folium cum flore, Weissdorn, Aubepine, WS 1442


  
## Motivation

<!-- This Motivation section was written only after all other sections were complete, so it reflects the full scope of the review. -->

Common hawthorn is a flowering rose-family shrub. Its leaves, flowers, and berries have a long European record as a heart tonic. Standardized leaf-and-flower extracts are sold as supplements and, in some countries, as registered herbal medicines. People who already manage blood pressure, training capacity, and long-term heart function look to hawthorn because trials have tested it for mild heart weakness and for blood pressure.

The best-studied products are European leaf-and-flower extracts taken for weeks to months. Early controlled studies reported better exercise tolerance and fewer symptoms of mild heart weakness. Later, larger studies that added hawthorn to modern heart drugs did not show a clear drop in major cardiac events, and one smaller study raised a question about early worsening. Blood-pressure studies are smaller and mixed.

This review examines the human evidence for common hawthorn as a cardiovascular longevity intervention: mechanisms, benefits and harms, who tends to respond, how products differ, and how those findings sit beside sleep, food, training, and blood-pressure control.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


  
## Recommended Reading

<!-- Real-time search 2026-08-16 for high-level overviews of common hawthorn / Crataegus. Web searches: "Rhonda Patrick hawthorn OR Crataegus", "Peter Attia hawthorn OR Crataegus", "Andrew Huberman hawthorn OR Crataegus", "Chris Kresser hawthorn OR Crataegus", "Life Extension hawthorn site:lifeextension.com", "hawthorn Crataegus site:lifespan.io". On-site searches: foundmyfitness.com/search?q=hawthorn (combo-supplement mention only); peterattiamd.com/?s=hawthorn+Crataegus (no results); hubermanlab.com/search?q=hawthorn (no hawthorn hits); chriskresser.com/?s=hawthorn (passing tea/alcohol-history mentions only); lifeextension.com congestive-heart-failure protocol (dedicated hawthorn subsection, updated 04/2025); lifespan.io/?s=hawthorn (unrelated person-name hits). Also searched narrative reviews and expert commentary. Excluded Grokipedia, Examine, ConsumerLab, systematic reviews, meta-analyses, encyclopedias/wikis, forums, and mainstream media. Five independent sources met the high-level-overview bar. -->

High-level overviews that frame common hawthorn's cardiovascular evidence, product types, and unresolved trial conflicts.

* [Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review](https://pubmed.ncbi.nlm.nih.gov/29080984/) - Holubarsch et al., 2018

  The SPICE principal investigator reviews WS 1442 mechanisms, older symptom trials, the mortality study, and post-marketing safety in one place.

* [Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease](https://pubmed.ncbi.nlm.nih.gov/22228939/) - Tassell et al., 2010

  A narrative review of mechanisms, clinical trials, and safety that also examines the HERB CHF progression analysis rather than ignoring it.

* [Hawthorn (Crataegus monogyna Jacq.): A Review of Therapeutic Potential and Applications](https://pubmed.ncbi.nlm.nih.gov/41599280/) - Kępińska-Pacelik & Biel, 2026

  A 2026 review of *Crataegus monogyna* chemistry and proposed uses, useful for separating the common species from Chinese hawthorn.

* [Heart Failure](https://www.lifeextension.com/protocols/heart-circulatory/congestive-heart-failure) - Sandhaus & Williams

  A frequently updated integrative heart-failure protocol that places hawthorn next to conventional care and other nutrients, with citations to the extract trials.

* [Health effects of hawthorn](https://pubmed.ncbi.nlm.nih.gov/20148500/) - Dahmer & Scott, 2010

  A concise *American Family Physician* overview of extracts, trial findings, adverse effects, and theoretical drug interactions for clinicians.

No dedicated hawthorn episodes or articles were found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Lifespan.io. FoundMyFitness only names hawthorn as one anthocyanin source in a multi-ingredient study note. Kresser mentions hawthorn tea in passing. Life Extension is the only priority source with substantial coverage.


  
## Grokipedia

<!-- Direct grokipedia.com search 2026-08-16 via browser. Query "hawthorn" returned place-name pages. Query "Crataegus" returned many species pages. Query "Crataegus monogyna" returned the dedicated botanical article as the first hit. Opened https://grokipedia.com/page/Crataegus_monogyna (title: Crataegus monogyna — Grokipedia). No separate clinical-extract article was present. -->

* [Crataegus monogyna](https://grokipedia.com/page/Crataegus_monogyna)

  Grokipedia's dedicated page for common hawthorn covers taxonomy, morphology, traditional use, and the species identity used in European extracts.


  
## Examine

<!-- Direct examine.com search 2026-08-16. Browser hit a Vercel security checkpoint; d-fetch returned 429; d-proxy-1 retrieved the genuine search pages. Query "hawthorn" and query "Crataegus" each returned only "Chinese Hawthorn" (Crataegus pinnatifida) at /supplements/chinese-hawthorn/. No dedicated Examine page for common hawthorn, C. monogyna, C. laevigata, or WS 1442 was present. -->

No dedicated Examine.com article for common hawthorn (*Crataegus monogyna* / *Crataegus laevigata*) was found as of 16 August 2026. Examine has a page for Chinese hawthorn (*Crataegus pinnatifida*), a related species used mainly in East Asian practice, not the European leaf-and-flower extracts in the heart-failure trials.


  
## ConsumerLab

<!-- Direct consumerlab.com search 2026-08-16. Browser hit a Cloudflare interstitial; d-proxy-1 retrieved the genuine search page at /search/?q=hawthorn. Results were CL Answers and clinical-update snippets inside broader blood-pressure and heart-health Q&As, plus unrelated recalls. No dedicated ConsumerLab product review or standalone hawthorn monograph was present. -->

No dedicated ConsumerLab product review of common hawthorn was found as of 16 August 2026. ConsumerLab discusses hawthorn only as a subsection inside broader blood-pressure and heart-health Q&A pages, not as a standalone tested-product article.


  
## Systematic Reviews

<!-- Real-time PubMed search 2026-08-16. Query: (Crataegus[Title/Abstract] OR "hawthorn extract"[Title/Abstract] OR "hawthorn berry"[Title/Abstract] OR WS-1442[Title/Abstract] OR "WS 1442"[Title/Abstract]) AND (systematic review[pt] OR meta-analysis[pt] OR "systematic review"[Title] OR "meta-analysis"[Title] OR metaanalysis[Title]). Returned 11 records. A first broader query that included "hawthorn" without a title/abstract lock mixed in many author-name hits and was discarded. Selected by relevance to common hawthorn, recency, size, and coverage of the claimed effect (heart failure, blood pressure) and the principal risk (adverse events). -->

Pooled analyses of common hawthorn extracts for heart-failure symptoms, blood pressure, and adverse events.

* [Hawthorn extract for treating chronic heart failure](https://pubmed.ncbi.nlm.nih.gov/18254076/) - Pittler et al., 2008

  Cochrane pooled 14 double-blind trials; hawthorn raised workload and eased breathlessness and fatigue versus placebo.

* [Hawthorn (Crataegus spp.) Clinically Significantly Reduces Blood Pressure in Hypertension: A Meta-Analysis of Randomized Placebo-Controlled Clinical Trials](https://pubmed.ncbi.nlm.nih.gov/40732315/) - Szikora et al., 2025

  Six placebo-controlled trials (n = 428) pooled a roughly 7 mmHg systolic drop; diastolic change was not significant.

* [Adverse-event profile of Crataegus spp.: a systematic review](https://pubmed.ncbi.nlm.nih.gov/16752934/) - Daniele et al., 2006

  Safety review of 24 human studies (5,577 people): mild dizziness, gastrointestinal complaints, headache, and palpitations predominated.

* [Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials](https://pubmed.ncbi.nlm.nih.gov/12798455/) - Pittler et al., 2003

  Earlier meta-analysis of eight heart-failure trials found a 7-watt workload gain and fewer symptoms.

* [Nutraceuticals in Patients With Heart Failure: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/31704198/) - Hopper et al., 2020

  Guideline-linked review of nutraceuticals in heart failure judged hawthorn trials too small to support a recommendation.


  
## Mechanism of Action

Common hawthorn leaf-and-flower extracts act on heart muscle and blood vessels through several overlapping paths. The main studied constituents are oligomeric procyanidins (short chains of plant polyphenols) and flavonoids such as vitexin, hyperoside, and rutin.

In isolated human heart muscle, the special extract WS 1442 raises contractile force by a cyclic-AMP-independent route (cyclic AMP is a cell messenger used by several heart drugs). The proposed path involves the sodium-potassium pump and sodium-calcium exchange, so the force-boosting effect is milder than that of digoxin and is not a digitalis-like action.

In arteries, WS 1442 phosphorylates endothelial nitric oxide synthase (the lining enzyme that makes nitric oxide, a relaxing gas) at serine 1177, increasing nitric oxide and widening vessels. Mild blockade of angiotensin-converting enzyme (an enzyme that tightens vessels) and antioxidant effects add to vasodilation. A competing human finding is the lack of a dose-linked change in flow-mediated dilation (an ultrasound test of nitric-oxide release), which leaves a nitric-oxide-independent route open.

The whole extract has no single half-life. Individual flavonoids are absorbed modestly, conjugated in the liver, and cleared over about 2–6 hours, so trials split the daily amount. Oligomeric procyanidins are poorly absorbed intact and act partly through gut metabolites. Distribution in humans is incompletely mapped; activity is described in heart muscle and vessel lining. The extract is not a selective single-receptor drug and is not a major substrate of one named cytochrome P450 liver enzyme in clinical studies.


  
## Historical Context & Evolution

Hawthorn fruit and flower appear in Dioscorides and later European herbals as a heart, digestive, and calming plant. Nineteenth-century American Eclectic physicians, following the Irish practitioner Green, used berry tincture for "heart weakness" and irregular pulse. German phytomedicine in the twentieth century shifted the official plant part to leaf with flower and standardized extracts to flavonoids or oligomeric procyanidins.

The German Commission E, a government herbal-monograph panel whose members do not sell hawthorn products, approved leaf-and-flower extract for New York Heart Association class II heart failure (mild limitation of ordinary activity). That monograph, plus manufacturer-sponsored German trials of WS 1442 and LI 132, moved hawthorn from folk tonic to a studied add-on. Dr. Willmar Schwabe GmbH, the manufacturer of WS 1442, funded much of that extract's clinical program. A [2003 meta-analysis](https://pubmed.ncbi.nlm.nih.gov/12798455/) and a [2008 Cochrane review](https://pubmed.ncbi.nlm.nih.gov/18254076/) of older randomized trials reported better exercise measures and symptoms.

The [2008 SPICE](https://pubmed.ncbi.nlm.nih.gov/19019730/) mortality trial and the [2009 HERB CHF](https://pubmed.ncbi.nlm.nih.gov/19789403/) functional trial then tested add-on use on top of contemporary drugs. SPICE, also Schwabe-funded, did not meet its primary cardiac-event endpoint. HERB CHF did not improve walk distance, and a secondary analysis reported more early progression. Those results did not erase the older symptom trials; they showed that the outcome, the background therapy, and the population matter. European herbal monographs still list leaf-and-flower extract for mild heart complaints. A [2025 blood-pressure meta-analysis](https://pubmed.ncbi.nlm.nih.gov/40732315/) reopened the hypertension question with mixed individual-trial results under a pooled systolic estimate.


  
## Expected Benefits

<!-- Dedicated benefit-profile search 2026-08-16: PubMed title searches for Crataegus / hawthorn extract / WS 1442 crossed with heart failure, hypertension, lipids, anxiety, and endothelial outcomes; fetches of Pittler 2003/2008, Holubarsch 2008 (SPICE), Zick 2008/2009 (HERB CHF), Walker 2002/2006, Asher 2012, Dalli 2011, Tauchert 2002, Weikl 1996, Szikora 2025, Zeng 2024, Eggeling 2011; plus Drugs.com monograph, Life Extension protocol, and Holubarsch 2018 narrative review. Benefits below cover the complete human profile for European common-hawthorn extracts. Chinese hawthorn (C. pinnatifida) digestive and lipid claims are a different species and are not treated as benefits of common hawthorn. -->

### Medium 🟩 🟩

#### Heart-Failure Symptom and Exercise-Capacity Support ⚠️ Conflicted

Older double-blind trials, mostly of WS 1442 or LI 132 added to then-standard drugs, reported better bicycle workload, lower pressure–heart-rate product (an index of cardiac oxygen demand), and less breathlessness and fatigue. The [2008 Cochrane review](https://pubmed.ncbi.nlm.nih.gov/18254076/) pooled those studies. The later [SPICE trial](https://pubmed.ncbi.nlm.nih.gov/19019730/) (2,681 people; Schwabe-funded) did not reduce the first cardiac event, and [HERB CHF](https://pubmed.ncbi.nlm.nih.gov/19789403/) found no gain in six-minute walk on contemporary therapy. The symptom signal and the event/function signal therefore disagree.

**Magnitude:** Cochrane: maximal workload +5.35 W (95% CI, confidence interval — the range likely to hold the true value, 0.71 to 10.00) and symptom score −5.47 (95% CI −8.68 to −2.26) versus placebo. SPICE: hazard ratio (relative event rate versus placebo) 0.95 for first cardiac event (95% CI 0.82 to 1.10; not significant).

#### Blood Pressure Reduction ⚠️ Conflicted

Smaller trials in mild hypertension or in type 2 diabetes reported modest pressure drops, clearest for diastolic pressure in [Walker et al. 2006](https://pubmed.ncbi.nlm.nih.gov/16762125/) (1,200 mg/day for 16 weeks). A [2025 meta-analysis](https://pubmed.ncbi.nlm.nih.gov/40732315/) of six placebo-controlled trials pooled a clinically noticeable systolic reduction. [Asher et al. 2012](https://pubmed.ncbi.nlm.nih.gov/22458601/) found no dose-linked change in flow-mediated dilation or blood pressure over 3.5 days, and a [2024 fruit-extract drink trial](https://pubmed.ncbi.nlm.nih.gov/39583031/) was null versus a calorie-matched placebo.

**Magnitude:** Pooled systolic change about −6.7 mmHg across 2–6 months in Szikora et al.; Walker 2006 diastolic change about −2.6 mmHg on hawthorn versus +0.5 mmHg on placebo, systolic not significant.

### Low 🟩

#### Blood Lipid Reduction

In 49 people with diabetes and coronary disease, *C. laevigata* leaf-and-flower extract (400 mg three times daily, 6 months, on statins — cholesterol-lowering drugs) lowered LDL cholesterol (low-density lipoprotein) within the hawthorn arm; the between-group contrast was not significant ([Dalli et al. 2011](https://pubmed.ncbi.nlm.nih.gov/21242072/)). A later fruit-drink trial was null.

**Magnitude:** Within-group LDL cholesterol 105 to 92.7 mg/dL at 6 months in Dalli et al.; between-group difference not significant.

#### Mild Anxiety Symptom Reduction

A 10-week pilot in mild essential hypertension reported a trend toward lower anxiety scores in those assigned hawthorn 500 mg/day ([Walker et al. 2002](https://pubmed.ncbi.nlm.nih.gov/11807965/)). Stronger anxiety data come from multi-herb products, not hawthorn alone.

**Magnitude:** Anxiety reduction was a non-significant trend (p = 0.094, the chance of seeing this result if there were no real effect) in one small factorial pilot; no controlled monopreparation (single-herb product) trial has published a confirmed effect size.

### Speculative 🟨

#### Endothelial Aging Protection

In aged rats, WS 1442 preserved endothelium-dependent relaxation. The basis is preclinical only; the short human flow-mediated-dilation study was negative.

#### Rhythm Stability

An open 1,011-person observational series of WS 1442 reported fewer exercise-related extra beats. No adequate randomized arrhythmia endpoint trial exists for the monopreparation.


  
## Benefit-Modifying Factors

* **Baseline blood pressure and symptom load:** Larger room to move appears when starting pressure or heart-failure symptoms are higher; near-normal readings leave little for a 5–7 mmHg-class effect to show.

* **Background heart-failure therapy:** Symptom gains were clearer on older, thinner drug regimens. On contemporary multi-drug therapy, add-on function and event benefits have not been shown.

* **Left-ventricular pump strength:** The [SPICE](https://pubmed.ncbi.nlm.nih.gov/19019730/) sudden-death subgroup hint was confined to less severely reduced ejection fraction (the share of blood the left ventricle pumps per beat; about 25–35%), not the weakest hearts.

* **Sex:** A pooled analysis of quantified extract trials found that baseline severity, not sex, tracked the size of the effect.

* **Age:** Most participants were middle-aged or older. Age itself is not a proven effect modifier; older users do have more dizziness and additive pressure-lowering.

* **Diabetes and coronary disease:** Walker (diabetes plus pressure drugs) and Dalli (diabetes plus coronary disease on statins) are the main comorbidity datasets; both are small.

* **Genetics:** No well-replicated variant — APOE4 (a fat-transport gene linked to heart and brain risk), MTHFR (a folate-processing gene), or CYP2C9 (a liver enzyme that clears many drugs) — is known to change hawthorn benefit.


  
## Potential Risks & Side Effects

<!-- Dedicated harm-profile search 2026-08-16: Daniele 2006 systematic safety review; SPICE and HERB CHF adverse-event sections; Zick 2008 progression analysis; Drugs.com hawthorn monograph (reviewed 31 Dec 2025); Page 2016 AHA statement on drugs that may worsen heart failure (PMID 27400984); Tankanow 2003 digoxin interaction RCT; Espinosa 2024 tejocote/oleander toxicity (different species/adulterant). Complete European monopreparation profile below. -->

### Medium 🟥 🟥

#### Dizziness and Lightheadedness

Dizziness and vertigo (a spinning sensation) were the most frequent nervous-system complaints in the [Daniele et al. 2006](https://pubmed.ncbi.nlm.nih.gov/16752934/) safety review and in older extract trials. The likely mechanism is vasodilation plus a small drop in pressure or heart rate. Events were usually mild and reversible after stopping or lowering the dose. SPICE reported adverse-event rates similar to placebo.

**Magnitude:** Dizziness/vertigo in 15 of 5,577 analyzable participants across included trials; overall adverse events 166/5,577 (~3%).

#### Digestive Upset

Nausea, abdominal discomfort, and other gastrointestinal complaints were the single largest adverse-event class in the [Daniele et al. 2006](https://pubmed.ncbi.nlm.nih.gov/16752934/) safety review. They were typically mild and transient. Isolated bleeding reports are treated separately below.

**Magnitude:** Gastrointestinal complaints in 24 of 5,577 trial participants.

### Low 🟥

#### Early Heart-Failure Progression ⚠️ Conflicted

A HERB CHF analysis found more early progression (death, hospital stay, or extra diuretic — a fluid-removing drug) on WS 1442 900 mg/day when ejection fraction was ≤35% ([Zick et al. 2008](https://pubmed.ncbi.nlm.nih.gov/18490196/)). SPICE did not show excess events. This secondary analysis of a small trial remains unreplicated.

**Magnitude:** Adjusted early-progression hazard 6.4 (95% CI 1.5 to 26.5) in HERB CHF; SPICE primary-event hazard 0.95 (not significant).

#### Palpitations

Palpitation was among the more frequent cardiac complaints in [Daniele et al. 2006](https://pubmed.ncbi.nlm.nih.gov/16752934/). Whether this reflects awareness of a slower or stronger beat, true extra beats, or reporting bias is unclear. Observational series also described fewer extra beats in some users.

**Magnitude:** Palpitation in 11 of 5,577 trial participants in Daniele et al.

#### Headache

Headache and migraine appeared at low rates in the [Daniele et al. 2006](https://pubmed.ncbi.nlm.nih.gov/16752934/) safety dataset and in product monographs. Severity was generally mild.

**Magnitude:** Headache in 9 and migraine in 8 of 5,577 trial participants.

#### Rash

Product monographs list rash with the other common hawthorn complaints. [Daniele et al. 2006](https://pubmed.ncbi.nlm.nih.gov/16752934/) recorded red skin rash only in WHO (World Health Organization) spontaneous reports, not as a leading trial event. Events were uncommon and usually mild.

**Magnitude:** Red skin rash in 2 of 18 WHO spontaneous reports in Daniele et al.; not among the leading trial adverse events.

#### Increased Bleeding Tendency

A [2016 American Heart Association statement](https://pubmed.ncbi.nlm.nih.gov/27400984/) — members do not sell hawthorn — listed an antiplatelet effect (making blood less likely to clot) that may raise bleeding risk with anticoagulants. [Daniele et al. 2006](https://pubmed.ncbi.nlm.nih.gov/16752934/) recorded two gastrointestinal hemorrhages in spontaneous reports only. Trials did not show a bleeding excess.

**Magnitude:** Two of 18 WHO spontaneous reports in Daniele et al. were gastrointestinal hemorrhage; trial datasets did not quantify a bleeding excess versus placebo.

### Speculative 🟨

#### Shared Heart-Muscle Effect with Digoxin

A crossover trial found no change in digoxin blood levels after three weeks of WS 1442 ([Tankanow et al. 2003](https://pubmed.ncbi.nlm.nih.gov/12817526/)). A force-of-contraction overlap remains a mechanistic concern only.

#### Liver Injury

Isolated case reports exist; monopreparation trials did not establish a liver-injury pattern. The basis is anecdotal.


  
## Risk-Modifying Factors

* **Starting blood pressure and heart rate:** Lower baseline pressure or a slow pulse raises the chance of dizziness and additive hypotension (low blood pressure) when other vessel-relaxing agents are on board.

* **Reduced ejection fraction and recent decompensation:** The [HERB CHF](https://pubmed.ncbi.nlm.nih.gov/18490196/) early-progression signal clustered in weaker pumps (ejection fraction ≤35%) and when heart-failure symptoms had recently worsened suddenly (decompensation), especially in the first weeks of add-on use.

* **Age:** Older adults dominate the trial base and are more prone to orthostatic dizziness (lightheadedness on standing) from vasodilation.

* **Sex:** No consistent sex difference in adverse-event rates is established for hawthorn monopreparations.

* **Genetics:** No validated pharmacogenetic marker is known to raise hawthorn-specific risk.

* **Allergy to the rose family:** Prior reactions to rose-family plants are the clearest predisposition to rash or hypersensitivity.


  
## Key Interactions & Contraindications

* **Antihypertensive drugs (lisinopril, losartan, amlodipine, metoprolol):** Caution. Additive vasodilation and pressure-lowering can cause dizziness or symptomatic hypotension. Mitigate by home pressure checks and by not starting another pressure-lowering agent in the same week.

* **Nitrates (nitroglycerin, isosorbide mononitrate):** Caution. Combined vessel relaxation can drop pressure. Separate new hawthorn starts from nitrate titration and monitor standing pressure.

* **PDE5 inhibitors (sildenafil, tadalafil; drugs that raise nitric-oxide signaling for erection):** Caution. Theoretical additive vasodilation. Avoid taking both in the same hour until individual pressure response is known.

* **Digoxin:** Monitor. Three-week WS 1442 coadministration did not change digoxin pharmacokinetics (how the drug moves through the body), but overlapping heart-muscle effects remain a reason to watch levels and symptoms.

* **Antiarrhythmics (amiodarone, flecainide):** Caution. Theoretical rhythm interaction; evidence is sparse. Rhythm monitoring if both are used.

* **Anticoagulants and antiplatelet drugs (warfarin, clopidogrel, aspirin):** Caution. An additive antiplatelet effect may raise bleeding risk. Watch for unusual bruising or bleeding; hold 7–14 days before procedures.

* **Other pressure-lowering supplements (garlic, hibiscus, beetroot, magnesium, CoQ10 / coenzyme Q10, L-arginine):** Caution. Additive effects on pressure are expected. Introduce one agent at a time.

* **Calming herbs (valerian, passionflower):** Monitor. Combination products exist; monopreparation sedation is not established, but combined drowsiness is possible.

**Populations who should avoid Common Hawthorn:**

* Known allergy to the rose family (Rosaceae)

* Pregnancy or lactation (human data are insufficient; animal studies have not shown birth defects)

* Acute decompensated heart failure or New York Heart Association class IV symptoms (symptoms at rest)

* Recent myocardial infarction (heart attack), typically within 90 days — not studied, unstable substrate

* Children and adolescents — essentially no controlled data

* Planned major surgery within two weeks — theoretical unstable blood pressure around the operation


  
## Risk Mitigation Strategies

* **Leaf-and-flower extract, not unmarked berry or "root":** Matches the trial material and avoids tejocote/oleander-adulterated weight-loss products that have caused heart block.

* **Start at 300–450 mg/day for 1–2 weeks:** Limits early dizziness and unmasks additive hypotension before the common 900 mg/day trial dose.

* **Split morning and evening doses:** Matches the short flavonoid half-life and the twice- or three-times-daily WS 1442 trial schedules, limiting peak dizziness from a single large dose.

* **Home blood-pressure and standing-symptom log for 4 weeks:** Detects additive hypotension and orthostatic dizziness while the extract is being added to existing drugs.

* **Do not use as the sole therapy for reduced-ejection-fraction heart failure:** The [HERB CHF](https://pubmed.ncbi.nlm.nih.gov/18490196/) progression signal and the [SPICE](https://pubmed.ncbi.nlm.nih.gov/19019730/)-null event result both argue against replacing proven heart-failure drugs.

* **Hold before elective surgery:** Stopping 7–14 days beforehand reduces unmeasured perioperative pressure swings.

* **Third-party-tested, species-labeled product:** Lowers the risk of wrong species, undeclared actives, or oleander-tainted "hawthorn root."


  
## Therapeutic Protocol

* **Leading extract:** WS 1442 (dry leaf-with-flower extract, ethanol 45%, 17.3–20.1% oligomeric procyanidins) is the best-characterized form. LI 132 (about 2.2% flavonoids) is the main alternative. Schwabe manufactures WS 1442.

* **Usual studied daily amount:** 600–900 mg/day of WS 1442-type extract (trial range 160–1,800 mg/day). [Tauchert 2002](https://pubmed.ncbi.nlm.nih.gov/12040357/) found 1,800 mg better than 900 mg for class III exercise capacity.

* **Split doses:** Two or three oral doses with meals. Half-lives of individual flavonoids are about 2–6 hours; there is no single extract half-life.

* **Time of day:** Morning and evening (and mid-day if three times daily). No circadian (body-clock) optimum is established.

* **Judging window:** Symptom and pressure changes, when they occur, are usually assessed at 6–8 weeks; heart-failure trials ran 8 weeks to 24 months.

* **Genetics:** No APOE4, MTHFR, COMT (an enzyme that breaks down stress and dopamine chemicals), or cytochrome-P450 variant is established as a dose-choice factor.

* **Sex:** Pooled trial data did not show a sex-specific dose adjustment.

* **Age:** Most trial participants were older adults. A lower start (300–450 mg/day) is the usual practical adjustment for dizziness risk, not a proven change in efficacy.

* **Baseline markers:** Higher starting pressure and more heart-failure symptoms were the settings with measurable movement; near-normal values leave little to gain.

* **Pre-existing conditions:** Type 2 diabetes and stable coronary disease appear in the Walker and Dalli datasets. Unstable coronary syndromes and class IV failure were excluded from the major trials.


  
## Discontinuation & Cycling

* **Intended horizon:** Trials treated people continuously for 8 weeks to 24 months. The extract is not inherently lifelong and is not a short "course" antibiotic-style therapy.

* **Withdrawal:** No withdrawal syndrome is described after stopping monopreparations.

* **Taper:** No taper is required for the extract itself. Blood-pressure and heart-failure drugs that were adjusted while hawthorn was on board may need re-checking after it is stopped.

* **Cycling:** Cycling is not used in the clinical literature to preserve effect. Continuous daily dosing is what the trials tested.

* **After a progression signal:** New breathlessness, sudden weight gain, or a diuretic increase during the first weeks is the scenario in which [HERB CHF](https://pubmed.ncbi.nlm.nih.gov/18490196/) recorded early worsening; those cases stopped or were escalated rather than cycled.


  
## Sourcing and Quality

* **Plant part:** European monographs and the major trials use leaf with flower (*Crataegi folium cum flore*), not berry-only powders and not "hawthorn root."

* **Species on the label:** *C. monogyna*, *C. laevigata* (synonym *C. oxyacantha*), or their hybrids. Chinese hawthorn (*C. pinnatifida*) and tejocote (*C. mexicana*) are different interventions.

* **Standardization:** Prefer a stated oligomeric-procyanidin content near 18% (WS 1442 class) or a stated flavonoid content near 2.2% (LI 132 class). Unstandardized berry capsules do not match the trial material.

* **Third-party testing:** NSF (independent product-testing body), USP (United States Pharmacopeia), or equivalent identity and contaminant testing matters because herbal products vary and because "hawthorn root" weight-loss items have been adulterated with oleander.

* **Named clinical brands:** Crataegutt / HeartCare (WS 1442) and Faros (LI 132) are the extracts behind most randomized data. Equivalent specification is more important than the brand name.

* **Avoid:** Tejocote-root slimming products and unlabeled multi-herb "heart tonics" that hide the dose.


  
## Practical Considerations

* **Time to effect:** Pressure and symptom changes, when present, are usually judged at 6–8 weeks. Event outcomes in [SPICE](https://pubmed.ncbi.nlm.nih.gov/19019730/) were measured over 24 months and were not significant.

* **Common pitfalls:** Using berry powder or tea and expecting WS 1442 trial results; adding hawthorn to several pressure-lowering drugs in the same week; treating hawthorn as a stand-alone heart-failure drug.

* **Regulatory status:** In the United States it is a dietary supplement, not an FDA (U.S. Food and Drug Administration)-approved heart-failure drug. In parts of Europe, leaf-and-flower extract is a registered traditional or well-established-use herbal medicine.

* **Cost and access:** Standardized extracts are inexpensive and widely sold. Cost is not a barrier compared with prescription heart-failure drugs.

* **Manufacturer evidence base:** Much of the WS 1442 literature, including [SPICE](https://pubmed.ncbi.nlm.nih.gov/19019730/), was funded by Schwabe. Independent replication on modern background therapy is thinner.


  
## Interaction with Foundational Habits

* **Sleep:** None established as a direct sleep effect. An indirect path is nighttime dizziness or a lower evening pressure. Combination calming products exist; the monopreparation is not a sleep drug.

* **Nutrition:** None as a nutrient depleter; indirect with food timing. Monographs give it with meals. It does not replace a pressure-oriented pattern such as DASH (Dietary Approaches to Stop Hypertension) or a Mediterranean pattern. Sugary "heart drinks" added calories in one null trial.

* **Exercise:** None as a hypertrophy blunter. Trials used bicycle or walk tests as outcomes. The practical conflict is new standing dizziness after a session, not a blocked training effect.

* **Stress management:** Indirect and unconfirmed. A small factorial pilot reported a trend toward lower anxiety. That does not replace breath work, sleep, or therapy as a stress tool.


  
## Monitoring Protocol & Defining Success

Before the first dose, a baseline set of pressure, heart-rate, and (if heart-failure history is present) pump-function measurements gives a personal reference. That set includes seated and standing blood pressure, resting heart rate, morning weight, and, when a clinician is already following heart-failure labs, NT-proBNP (a blood marker released when the heart wall is stretched) plus a recent ejection-fraction value. Liver enzymes are optional and are more relevant if other hepatotoxic (liver-stressing) agents are in use.

Repeat home pressure and standing symptoms at 2 weeks and 4 weeks, then a fuller set at 8–12 weeks (the usual time to judge symptoms). If the extract continues, recheck every 3–6 months, or sooner after any change in blood-pressure or heart-failure drugs.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
| --- | --- | --- | --- |
| Seated systolic / diastolic blood pressure | 110–120 / 70–80 mmHg | Tracks the intended pressure effect and additive hypotension | Conventional office target is often <130/80 mmHg; measure seated, same arm, morning |
| Standing systolic blood pressure | Drop <10 mmHg from seated, no symptoms | Detects orthostatic dizziness from vasodilation | Conventional orthostatic cut-off is often a ≥20 mmHg systolic drop; check at 1 minute and 3 minutes; pair with symptom notes |
| Resting heart rate | 55–70 beats/min | Flags excessive slowing when used together with beta blockers | Beta blockers are heart-rate-slowing drugs. Conventional resting range is often 60–100 beats/min; morning, seated, 60-second count |
| Morning weight | Stable versus the person's own 7-day baseline | Early fluid gain is how [HERB CHF](https://pubmed.ncbi.nlm.nih.gov/18490196/)-type worsening often shows | Same scale, after voiding; +2 lb (1 kg) in a day is a prompt to reassess |
| NT-proBNP | As low as possible; no single "optimal" hawthorn target | Confirms that add-on use is not quietly worsening wall stretch | Conventional rule-out is often <125 pg/mL; fasting not required |
| Left-ventricular ejection fraction | ≥55% if previously normal; otherwise track change from the person's own baseline | Places the user relative to the [HERB CHF](https://pubmed.ncbi.nlm.nih.gov/18490196/) ≤35% subgroup | Imaging, not a blood test; do not repeat without a clinical reason |
| ALT | <25–30 U/L (functional); conventional often <40–55 U/L | Optional liver-safety check if other liver-stressing agents are used | ALT is alanine aminotransferase, a liver enzyme. Non-fasting acceptable; isolated mild rises are nonspecific |

Qualitative markers:

* Breathlessness on a familiar flight of stairs or walk

* Energy and afternoon fatigue

* Ankle swelling or tighter shoes

* Lightheadedness on standing

* Palpitations

* Sleep continuity after evening doses


  
## Emerging Research

* **Add-on hawthorn versus ketones in stable heart failure:** [NCT07166965](https://clinicaltrials.gov/study/NCT07166965) is enrolling about 45 New York Heart Association class II–III patients at Thomas Jefferson University into hawthorn extract, ketone monoester, or placebo for 8 weeks, with exercise capacity and heart-structure imaging as primary measures.

* **Blood-pressure meta-analysis still thin:** [Szikora et al. 2025](https://pubmed.ncbi.nlm.nih.gov/40732315/) pooled only six trials. Larger, longer, extract-standardized pressure studies could raise or flatten the current ~7 mmHg systolic estimate.

* **HERB CHF progression signal unreplicated:** The [Zick et al. 2008](https://pubmed.ncbi.nlm.nih.gov/18490196/) early-worsening analysis remains the main evidence that could weaken add-on use in reduced-ejection-fraction failure; no dedicated modern replication has reported.

* **Sudden-death subgroup from SPICE:** The [SPICE](https://pubmed.ncbi.nlm.nih.gov/19019730/) 39.7% relative reduction in sudden death at 24 months in the ejection-fraction ≥25% subgroup was not the primary endpoint and has not been confirmed in a purpose-built trial.

* **Species split:** Work on *C. pinnatifida* (lipids, liver fat) is often marketed as "hawthorn" but does not automatically extend to common-hawthorn leaf-and-flower extract.


  
## Conclusion

Common hawthorn is a rose-family plant whose leaf-and-flower extracts have been studied mainly as an add-on for mild heart weakness and, in smaller work, for blood pressure. Older controlled trials and pooled analyses reported better exercise tolerance and fewer mild heart-failure symptoms. Later, larger studies that added hawthorn to modern heart-failure drugs did not show a clear drop in major cardiac events, and one smaller modern trial found no functional gain and earlier worsening. Blood-pressure evidence is modest and mixed. Lipid and mood findings are thin.

The extract is generally well tolerated. Usual complaints are dizziness, digestive discomfort, headache, and a racing or pounding heartbeat. Additive pressure-lowering with blood-pressure drugs and other vessel-relaxing supplements is the main practical interaction. A government herbal panel — that panel does not sell hawthorn — approved the leaf-and-flower extract for mild heart weakness. A cardiology society statement — that society does not sell hawthorn — also listed a possible extra bleeding tendency with blood thinners. A drug-level study did not show a change in blood levels of a common heart medicine, but combined heart-drug use still belongs under monitoring. Much of the best-known extract literature was funded by the manufacturer of that extract.

For a health-optimizing adult, hawthorn is a botanical with a limited and conflicted cardiovascular finding — not a longevity drug, and not a replacement for blood-pressure control, training, sleep, or proven heart-failure medicines. Product quality varies; leaf-and-flower extracts matched to the trial products are the form that matches the evidence.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**